Rifamycin SV is under development for treatment of travelers ' diarrhea ( TD ) in a new oral formulation , Rifamycin SV MMX ( RIF-MMX ; Santarus Inc. , San Diego , CA , USA ) , which targets its delivery to the colon , making it a unique rifamycin drug .